Matches in SemOpenAlex for { <https://semopenalex.org/work/W1487489382> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W1487489382 endingPage "36" @default.
- W1487489382 startingPage "30" @default.
- W1487489382 abstract "Both private and public sector see a bewildering clinical array of patients taking failing antiretroviral (ARV) regimens. We intend this article to provide a practical guide to help clinicians understand and manage ARV drug resistance in an African context. ARV resistance is a rapidly evolving field, requiring expertise in dealing with a wide range of situations. Much of the information we have on ARV resistance is from populations in the developed world where clade B is the biggest problem, while in most of Africa clade C is the commonest infection. Southern Africa is faced with the daunting prospect of putting several hundred thousand people on ARV therapy (ART) in the next few years.1 ART is the only effective option available to people with advanced HIV disease, and is remarkably effective in improving quality of life, increasing lifespan, dramatically decreasing the burden of opportunistic disease, and returning people to productive life.2The levels of adherence demanded by ARV regimens are extremely high relative to any other chronic disease. The South African government's Comprehensive Care for HIV/AIDS in the Public Health Sector3,4 programme has a 'second-line' ARV regimen (Fig. 1), specifically as a safety net for people failing the first-line regimen. Other countries do not have this luxury. The SA second-line regimen is more difficult to take, has greater toxicity, and is more expensive than the first-line treatment. ARV resistance often compromises future treatment options. The choice of regimens in the SA programme maximises the use of available drugs in this country. Our experience of private practitioners in South Africa is that they use a range of drug regimens other than those recommended in the government guidelines. There is no effective mechanism to enforce use of the government's recommended drug regimens, but we feel that they are the most rational use of drugs currently available in SA and that deviation from guidelines in routine use should be discouraged, unless alternative options exist. AZT/3TC is still a popular combination, and there are excellent data to support its use as the nucleoside reverse transcriptase inhibitor (NRTI) backbone in first-line therapy, but the alternatives available when resistance to this option develops (i.e. d4T with ddI) are very toxic. In other countries, alternative regimens may be more appropriate.While we have focused on adult ARV choices in this article, the same principles generally hold for children, although choice of drugs is currently different. Again, we recommend the use of the SA guidelines, published in the November 2005 Journal. Southern African Journal of HIV Medicine Vol. 7 (1) 2006: pp. 30-36" @default.
- W1487489382 created "2016-06-24" @default.
- W1487489382 creator A5054489645 @default.
- W1487489382 creator A5071956205 @default.
- W1487489382 creator A5078852155 @default.
- W1487489382 creator A5083468573 @default.
- W1487489382 date "2006-03-01" @default.
- W1487489382 modified "2023-09-27" @default.
- W1487489382 title "Antiretroviral drug resistance: A guide for the southern African clinician" @default.
- W1487489382 hasPublicationYear "2006" @default.
- W1487489382 type Work @default.
- W1487489382 sameAs 1487489382 @default.
- W1487489382 citedByCount "0" @default.
- W1487489382 crossrefType "journal-article" @default.
- W1487489382 hasAuthorship W1487489382A5054489645 @default.
- W1487489382 hasAuthorship W1487489382A5071956205 @default.
- W1487489382 hasAuthorship W1487489382A5078852155 @default.
- W1487489382 hasAuthorship W1487489382A5083468573 @default.
- W1487489382 hasConcept C114851261 @default.
- W1487489382 hasConcept C121426985 @default.
- W1487489382 hasConcept C126322002 @default.
- W1487489382 hasConcept C138885662 @default.
- W1487489382 hasConcept C141071460 @default.
- W1487489382 hasConcept C151730666 @default.
- W1487489382 hasConcept C159110408 @default.
- W1487489382 hasConcept C162324750 @default.
- W1487489382 hasConcept C18903297 @default.
- W1487489382 hasConcept C2778137410 @default.
- W1487489382 hasConcept C2779134260 @default.
- W1487489382 hasConcept C2779343474 @default.
- W1487489382 hasConcept C2779951463 @default.
- W1487489382 hasConcept C2781413609 @default.
- W1487489382 hasConcept C3013748606 @default.
- W1487489382 hasConcept C41895202 @default.
- W1487489382 hasConcept C50522688 @default.
- W1487489382 hasConcept C512399662 @default.
- W1487489382 hasConcept C57473165 @default.
- W1487489382 hasConcept C71924100 @default.
- W1487489382 hasConcept C83864248 @default.
- W1487489382 hasConcept C86803240 @default.
- W1487489382 hasConcept C89423630 @default.
- W1487489382 hasConceptScore W1487489382C114851261 @default.
- W1487489382 hasConceptScore W1487489382C121426985 @default.
- W1487489382 hasConceptScore W1487489382C126322002 @default.
- W1487489382 hasConceptScore W1487489382C138885662 @default.
- W1487489382 hasConceptScore W1487489382C141071460 @default.
- W1487489382 hasConceptScore W1487489382C151730666 @default.
- W1487489382 hasConceptScore W1487489382C159110408 @default.
- W1487489382 hasConceptScore W1487489382C162324750 @default.
- W1487489382 hasConceptScore W1487489382C18903297 @default.
- W1487489382 hasConceptScore W1487489382C2778137410 @default.
- W1487489382 hasConceptScore W1487489382C2779134260 @default.
- W1487489382 hasConceptScore W1487489382C2779343474 @default.
- W1487489382 hasConceptScore W1487489382C2779951463 @default.
- W1487489382 hasConceptScore W1487489382C2781413609 @default.
- W1487489382 hasConceptScore W1487489382C3013748606 @default.
- W1487489382 hasConceptScore W1487489382C41895202 @default.
- W1487489382 hasConceptScore W1487489382C50522688 @default.
- W1487489382 hasConceptScore W1487489382C512399662 @default.
- W1487489382 hasConceptScore W1487489382C57473165 @default.
- W1487489382 hasConceptScore W1487489382C71924100 @default.
- W1487489382 hasConceptScore W1487489382C83864248 @default.
- W1487489382 hasConceptScore W1487489382C86803240 @default.
- W1487489382 hasConceptScore W1487489382C89423630 @default.
- W1487489382 hasIssue "1" @default.
- W1487489382 hasLocation W14874893821 @default.
- W1487489382 hasOpenAccess W1487489382 @default.
- W1487489382 hasPrimaryLocation W14874893821 @default.
- W1487489382 hasRelatedWork W1557613478 @default.
- W1487489382 hasRelatedWork W1820583074 @default.
- W1487489382 hasRelatedWork W1964881216 @default.
- W1487489382 hasRelatedWork W1985782327 @default.
- W1487489382 hasRelatedWork W2013940774 @default.
- W1487489382 hasRelatedWork W2022157401 @default.
- W1487489382 hasRelatedWork W2022232445 @default.
- W1487489382 hasRelatedWork W2038619363 @default.
- W1487489382 hasRelatedWork W2049499076 @default.
- W1487489382 hasRelatedWork W2097762704 @default.
- W1487489382 hasRelatedWork W2102997632 @default.
- W1487489382 hasRelatedWork W2110113769 @default.
- W1487489382 hasRelatedWork W2115652810 @default.
- W1487489382 hasRelatedWork W2132439494 @default.
- W1487489382 hasRelatedWork W2137456039 @default.
- W1487489382 hasRelatedWork W2188034476 @default.
- W1487489382 hasRelatedWork W1652446574 @default.
- W1487489382 hasRelatedWork W2274193574 @default.
- W1487489382 hasRelatedWork W2276498209 @default.
- W1487489382 hasRelatedWork W2313310439 @default.
- W1487489382 hasVolume "7" @default.
- W1487489382 isParatext "false" @default.
- W1487489382 isRetracted "false" @default.
- W1487489382 magId "1487489382" @default.
- W1487489382 workType "article" @default.